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eta-Blockade Mitigates Exercise
lood Pressure in Hypertensive Male Patients
eter Kokkinos, PHD, Christina Chrysohoou, MD, PHD, Demosthenes Panagiotakos, PHD,
uneet Narayan, MD, Michael Greenberg, MD, Steve Singh, MD
ashington, DC
OBJECTIVES The purpose of this study was to determine the antihypertensive agent(s) more likely to
mitigate an exaggerated rise in exercise blood pressure (BP) in hypertensive patients.
BACKGROUND An exaggerated rise in exercise BP is associated with increased cardiovascular risk. There are
no recommendations for treating such response.
METHODS Participants were hypertensive men (n  2,318; age 60  10 years), undergoing a routine
exercise test at the Veterans Affairs Medical Center, Washington, DC. Antihypertensive
therapy included angiotensin-converting enzyme inhibitors (n  437), calcium-channel
blockers (n  223), diuretics (n  226), and combinations (n  1,442), beta-blockers alone
(n  201) or in combination with other antihypertensive agents (n  467), and none (n 
208). Exercise BP, heart rate (HR) and rate-pressure product (RPP) at maximal and
submaximal workloads were assessed.
RESULTS After adjusting for covariates, patients treated with beta-blockers or beta-blocker–based
therapy had significantly lower BP, HR, and RPP at 5 and 7 metabolic equivalents (METs)
and peak exercise than those treated with any other antihypertensive agent or combina-
tion (p  0.05). The likelihood of achieving an exercise systolic BP of 210 mm Hg was
68% lower (odds ratio 0.32, 96% confidence interval 0.2 to 0.53) in the beta-blocker–based
therapy versus other medications. African Americans exhibited higher BP and HR than
Caucasians at all exercise workloads regardless of antihypertensive therapy and had over a 90%
higher likelihood for an abnormal exercise BP response. This risk was attenuated by 35% with
a beta-blocker–based therapy.
CONCLUSIONS Significantly lower exercise BP, HR, and RPP levels are achieved with beta-blocker–based
therapy than with other antihypertensive agents regardless of race. However, BP was better
controlled in Caucasians than in African Americans regardless of antihypertensive
therapy. (J Am Coll Cardiol 2006;47:794–8) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.057Cardiology Foundation
h
r
i
k
s
g
s
c
m
d
v
M
S
w
C
w
w
r
An abnormal rise in systolic blood pressure (BP) during
xercise is associated with left ventricular hypertrophy
LVH) (1,2), cardiovascular morbidity and mortality, or an
xercise-induced acute cardiovascular event (3–6). At the
ery least, it often interferes with the completion of the exercise
olerance test (ETT) and prevents the accurate evaluation of
otential or existing coronary heart disease (CHD).
The metabolic demand of many leisure and routine daily
ctivities of middle-aged individuals is approximately 5 to 7
etabolic equivalents (METs) (7). Thus, it is reasonable to
ssume that the blood pressure (BP) response at workloads
f 5 to 7 METs during a graded ETT reflects very closely
he BP during daily activities (2). Relatively high BP levels
ay prevail in hypertensive patients engaging in routine
aily activities, and this may influence cardiac structure and
unction. We and others have reported strong and signifi-
ant associations among exercise BP at the intensities of 5 to
METs, BP during working hours, and left ventricular
ass (8,9). An even greater concern is the BP response of
From the Cardiology Division, Veterans Affairs and Georgetown University
edical Centers, Washington, DC.H
Manuscript received July 5, 2005; revised manuscript received August 31, 2005,
ccepted September 19, 2005.ypertensive patients engaging in strenuous manual or
ecreational activities that require repetitive bursts of max-
mal or near maximal effort, such as snow-shoveling, bas-
etball, tennis, etc. The repetitive BP peaks triggered during
uch activities may expose the hypertensive patient to a
reater risk for an acute cardiovascular event.
Recommendations for treating an exaggerated BP re-
ponse during exercise are not established and clinicians
onfronted with such response have no guidelines for
edical therapy. We sought to determine the BP response
uring exercise in hypertensive male patients receiving
arious antihypertensive medications.
ETHODS
tudy population. During 1996 to 2005, a routine ETT
as administered to 3,755 men at the Veterans Affairs Medical
enter, Washington, DC. Of these, 2,318 (age 60 10 years)
ere hypertensive and included in the study. Hypertension
as defined by the clinical history in the patient’s medical
ecord. Approximately 74% (n  1,725) were African
merican, 24% (n  545) Caucasian, and 2% (n  48)
ispanic and other races. Owing to the small sample size,
H
a
t
z
c
2
“
b
r
w
M
t
a
m
w
j
E
t
s
A
t
h
v
b
l
t
t
e
o
E
p
I
a
d
s
o
w
S
m
a
c
t
w
(
a
i
c
t
v
L
t
m
f
r
t
A
a
m
t
h
d
f
t
t
A
(
R
B
t
m
t
w
r
p
p
H
r
d
t
3
(
1
a
p
(
A
t
t
E
795JACC Vol. 47, No. 4, 2006 Tester et al.
February 21, 2006:794–8 Beta-Blockade in Hypertensive Male Patientsispanics and other races were combined with Caucasians in
ll analyses. All subjects gave a written consent prior to ETT.
About 47% (n  1,087) of the patients were on antihyper-
ensive monotherapy consisting of angiotensin-converting en-
yme inhibitors (ACE-I) (n  437), beta-blockers (n  201),
alcium-channel blockers (CCB) (n  223), or diuretics (n 
26). In addition to monotherapy groups, we established the
beta-blocker–based therapy” and “Other Meds” groups. The
eta-blocker–based therapy group (n 668) included patients
eceiving a beta-blocker alone (n  201) or in combination
ith any other antihypertensive agent (n  467). The Other
eds group (n  1,442) included patients receiving mono-
herapy (n  886), or combination therapy (n  556) of any
ntihypertensive agents that excluded beta-blockers. The re-
aining 208 (9%) were untreated.
All demographic, medical, and medication information
as obtained from patients’ computerized medical records
ust before ETT.
xercise assessments. All patients underwent an ETT on
he standard Bruce protocol (10). Patients were included in this
tudy if they did not have a positive ETT based on the
merican College of Cardiology/American Health Associa-
ion guidelines (11), impaired chronotropic response (12),
istory of an implanted pacemaker, use of digoxin, congenital
alvular heart disease, pre-excitation syndrome, or left bundle
ranch block.
Peak exercise time was recorded in minutes. Peak work-
oad was estimated as METs (10). Patients were encouraged
o exercise until volitional fatigue in the absence of symp-
oms or other indicators of ischemia. For a more accurately
stimated workload, the patients were not allowed to lean
n the handrails.
Supine resting BP was assessed after 5 min of rest.
xercise BP was recorded at 2 min of each exercise stage, at
eak exercise, and within 1, 3, and 5 min during recovery.
ndirect arm-cuff sphygmomanometry was used for all BP
ssessments.
Additional parameters recorded were body weight, height,
aily cigarette smoking habits as reported by the patient, total
erum cholesterol and fasting blood glucose levels, and history
f diabetes and other chronic diseases. Body mass index (BMI)
Abbreviations and Acronyms
ACE-I  angiotensin-converting enzyme inhibitors
BMI  body mass index
BP  blood pressure
CCB  calcium-channel blockers
CHD  coronary heart disease
CI  confidence interval
ETT  exercise tolerance test
HR  heart rate
METs  metabolic equivalents
OR  odds ratio
RPP  rate pressure productas calculated as weight (kg) divided by height (m)2. etatistical analysis. Continuous variables are presented as
ean  standard deviation and categorical variables as
bsolute and relative frequencies (%). Associations between
ategorical variables were tested using Pearson chi-square
est. Blood pressure comparisons between treatment groups
ere performed by the Student t test, Mann-Whitney test
for the skewed variable exercise duration), and one-way
nalysis of variance. The Bonferroni rule to correct for
nflation in the type-I error was applied with multiple
omparisons. Normality of the dependent variables was
ested by the Kolmogorov-Smirnov test, and equality of
ariances between treatment groups was tested by the
evene test. Fixed effects general linear models were applied
o evaluate differences on BP measurements between treat-
ent groups, after controlling for various potential con-
ounders. In particular, age, race, smoking, BMI, and
esting BP were individually entered in the models and
ested for their confounding effect on treatment groups.
dditionally, the interactions between treatment groups
nd the aforementioned variables were tested. Finally,
ultiple logistic regression analysis was applied to evaluate
he association between treatment groups on the likelihood of
aving abnormal systolic BP response (i.e., 210 mm Hg)
uring exercise, after controlling for various potential con-
ounders as mentioned above. Deviance residuals were used
o evaluate models’ goodness-of-fit. A p value of 0.05 of
wo-sided tests was considered to be statistically significant.
ll statistical analyses were performed in SPSS software
version 12.0, SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics. Patient clinical characteristics by
reatment group are presented in Table 1. Comparisons are
ade among the groups defined as “beta-blocker–based
herapy,” “Other Meds,” and “Untreated.” Patients treated
ith beta-blocker–based therapy had lower resting heart
ate (HR) compared with those treated with other antihy-
ertensive medications. Age, BMI, exercise duration, and
eak METs were similar between the two treated groups.
ypertensive untreated patients had significantly higher
esting systolic and diastolic BP, higher HR, longer exercise
uration, and higher peak MET level when compared with
he other groups (Table 1).
Other clinical characteristics included 803 (35%) diabetic;
18 (14%) with total serum cholesterol of 200 mg/dl, 1,035
45%) obese (BMI 29.9 kg/m2), 579 (25%) smokers, and
27 (6%) with family history of CHD. No significant associ-
tions were observed between treatment groups and the
revalence of high total cholesterol levels (p 0.24), obesity
p  0.87), and smoking habits (p  0.32). However,
frican Americans and diabetics were more likely to be
reated with ACE-I than other antihypertensive medica-
ions (p  0.001).
xercise parameters. The mean values of exercise param-ters at 5 and 7 METs, (3 and 6 min of exercise on the
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Beta-Blockade in Hypertensive Male Patients February 21, 2006:794–8ruce protocol) and peak exercise by treatment group are
resented in Table 2. Unadjusted analysis revealed that
atients in the beta-blocker–based therapy had significant
ower BP and HR at 5 and 7 METs and peak exercise
ompared with untreated patients and those treated with
ther medications.
To account for possible confounding effects of the previ-
us findings by differences in BMI, smoking, resting BP,
nd age, we adjusted for these potential confounders.
eneralized linear models revealed that patients on beta-
locker–based therapy still had lower systolic BP at 5 METs
beta-coefficient  standard error: 14.2  1.2 mm Hg; p 
.001), at 7 METs (15.5  1.5 mm Hg; p  0.001), and at
eak of exercise (15.2  1.3 mm Hg; p  0.001), when
ompared with patients treated with other antihypertensive
gents. Similarly, the exercise diastolic BP in these patients
as lower at 5 METs (2.4  0.02 mm Hg, p  0.014), 7
ETs (2.06 1.2 mm Hg; p 0.08), and peak of exercise
orkloads (1.9 1.1 mm Hg; p 0.007), as was HR at the
ame workloads (11.9  1.2 beats/min [p  0.001], 12.8 
.5 beats/min [p  0.001], and 17.1  1.2 beats/min [p 
.001], respectively). Subsequently, the rate-pressure prod-
ct (RPP) at these workloads also was significantly lower
Table 2).
When we considered monotherapy, the findings were
imilar. More specifically, the systolic BP, HR, and RPP at
Table 1. Clinical Characteristics of the Patient
Beta-Blocker–Ba
Number of patients 668
Age (yrs) 61  11
Body mass index (kg/m2) 29.9  5.8
Resting HR (beats/min) 66  12
Resting SBP (mm Hg) 129  19
Resting DBP (mm Hg) 80  11
Exercise duration (s) 399  148
METs (3.5 ml/O2/kg/min) 6.6  2.1
*The p values derived from analysis of variance for compariso
†Bonferroni-corrected probability value 0.05 for the post-h
groups vs. beta-blockers. ‡Bonferroni-corrected probabili
antihypertensive agents or untreated groups vs. beta-blocker
DBP  diastolic blood pressure; HR  heart rate; MET
Table 2. Exercise Parameters of Patients on C
Beta-Block
Number of patients 668
HR (beats/min) at 5 METs 103 
SBP (mm Hg) at 5 METs 153 
DBP (mm Hg) at 5 METs 85 
HR (beats/min) at 7 METs 116 
SBP (mm Hg) at 7 METs 166 
DBP (mm Hg) at 7 METs 86 
Peak HR (beats/min) 127 
Peak SBP (mm Hg) 177 
Peak DBP (mm Hg) 89 
RPP at 5 METs 15,929 
RPP at 7 METs 19,388 
RPP at peak exercise 22,800 *The p values derived from Student t test that evaluated difference
RPP  rate pressure product (HR · SBP); other abbreviations aand 7 METs and at peak of exercise were significantly
ower in patients treated with beta-blockers compared with
hose treated with CCBs, diuretics, or ACE-I (Table 3).
Intraracial comparisons revealed that both African Amer-
cans and Caucasians treated with beta-blocker–based ther-
py had lower BP, HR, and RPP at submaximal (5 and 7
ETs) and maximal workloads than those on other med-
cation (p  0.001). There was no treatment-by-race
nteraction for exercise BP, HR, or RPP (p  0.4).
Despite the lack of treatment-by-race interaction, we
robed for racial differences. Inter-racial comparisons re-
ealed that African Americans had consistently higher HR and
P than Caucasians regardless of antihypertensive regimen.
ore specifically, the resting BP of African Americans on
eta-blocker–based therapy was about 7/4 (2/1) mm Hg
igher than that of Caucasians on the same therapy.
imilarly, the BP at 5 and 7 METs and peak exercise was
igher in African Americans by 11/6 (2/1) mm Hg, 6/6
2/1) mm Hg, and 12/7 (2/1) mm Hg, respectively (all
 0.001). Age and BMI were similar. Comparisons
egarding antihypertensive medications other than beta-
lockers revealed similar findings. The BP of African
mericans was higher than Caucasians by approximately
/6 (2/1) mm Hg, 9/6 (2/1) mm Hg, and 7/6 (2/1)
m Hg at 5 METs, 7 METs, and peak exercise, respec-
ively. Resting BP and BMI were similar, but Caucasians
Treatment Group
Other Meds Untreated p*
1,442 208
59  10‡ 59  11‡ 0.002
29.8  5.2 29.5  5.2 0.69
75  14‡ 73  15‡ 0.001
131  19 142  18‡ 0.001
80  11 88  10‡ 0.001
418  168‡ 152  176‡ 0.001
7.0  2.4† 7.5  2.6‡ 0.001
een beta-blockers vs. other medication or untreated groups.
parisons between other antihypertensive agents or untreated
e 0.01 for the post-hoc comparisons between other
etabolic equivalent; SBP  systolic blood pressure.
nation Therapy
sed Other Meds p*
1,442
118  16 0.001
167  26 0.001
87  13 0.1
130  19 0.001
181  28 0.001
87  14 0.1
149  17 0.001
193  28 0.001
90  15 0.1
19,934  4,804 0.001
24,098  5,287 0.001
28,713  5,632 0.001s by
sed
ns betw
oc com
ty valuombi
er–Ba
17
28
13
17
27
16
21
28
14
4,688
5,118
6,086s between beta-blockers and other medication groups.
s in Table 1.
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February 21, 2006:794–8 Beta-Blockade in Hypertensive Male Patientsere slightly older (all p  0.005). Similarly, findings were
evealed for HR and rate-pressure product, at all exercise
evels (all p  0.001; data not presented).
Because exercise systolic BP of 210 mm Hg is consid-
red significant for developing LVH (1), we categorized
atients into those who achieved this BP level (n  618) or
id not achieve it (n  1,700). After controlling for age,
ace, and resting BP levels, the likelihood of systolic BP
f 210 mm Hg during exercise in those treated with
eta-blockers in combination with other antihypertensive
gents (beta-blocker–based) therapy was 68% lower (odds
atio [OR]  0.32; 95% confidence interval [CI] 0.2 to
.53) compared with those treated with combination
herapy of other antihypertensive agents. When mono-
herapy was considered, the likelihood of exercise systolic
P of 210 mm Hg was 58% lower in those treated with
eta-blockers compared with those treated with ACE-I
OR  0.42; 95% CI 0.25 to 0.71), 74% lower compared
ith those treated with CCB (OR  0.26; 95% CI 0.15 to
.46), and 64% lower compared with those treated with
iuretics (OR  0.36; 95% CI 0.20 to 0.64).
When we stratified by race we observed that African
mericans were at higher risk of having exercise systolic BP
f 210 mm Hg compared with Caucasians (OR  1.91;
5% CI 1.45 to 2.53) after adjusting for age, BMI, and
esting BP. Additional multiadjusted analysis revealed that
he use of beta-blockers in African Americans attenuated
he effect of race on the likelihood of having an exaggerated
xercise BP response by 35% (OR  0.65; 95% CI 0.4 to
.0).
ISCUSSION
e retrospectively assessed the BP response during exercise
n 2,318 hypertensive patients treated with various antihy-
ertensive medications. We observed that the use of beta-
lockers alone or in combination with other antihyperten-
ive agents was associated with lower systolic and diastolic
able 3. Exercise Parameters of Patients on Monotherapy
Beta-Blockers ACE-I
umber of patients 201 437
R (beats/min) at 5 METs 106  17 119  17†
BP (mm Hg) at 5 METs 152  26 164  25†
BP (mm Hg) at 5 METs 84  13 86  13†
R (beats/min) at 7 METs 119  18 131  16‡
BP (mm Hg) at 7 METs 164  25 178  27†
BP (mm Hg) at 7 METs 85  12 86  15
eak HR (beats/min) 132  22 150  17‡
eak SBP (mm Hg) 176  30 190  26‡
eak DBP (mm Hg) 88  13 90  15
PP at 5 METs 16,246  4,483 19,689  4,739‡
PP at 7 METs 19,757  5,258 23,671  5,174‡
PP at peak exercise 23,328  6,191 28,494  5,379‡
The p values derived from analysis of variance for the comparisons between treatm
etween other antihypertensive agents or untreated groups vs. beta-blockers. ‡Bon
ntihypertensive agents or untreated groups vs. Beta-blockers.
ACE-I  angiotensin-converting enzyme inhibitors; CCB  calcium-channel blP, HR, and RPP at the absolute submaximal workloads of sand 7 METs, as well as at peak exercise, compared with
he use of ACE-I, CCB, and diuretics as monotherapy or in
arious combinations. The average systolic BP at 5 and 7
ETs was lower by approximately 14 and 15 mm Hg,
espectively, and by 16 mm Hg at peak exercise, when
ompared with patients treated with other antihypertensive
gents. Moreover, beta-blockade–based therapy was associ-
ted with a lower likelihood of having an abnormal systolic
P response (systolic BP 210 mm Hg) during exercise,
ven after all adjustments for possible confounders were
onsidered. These findings lead to the conclusion that the
se of beta-blockers as monotherapy or in combination with
ther antihypertensive agents mitigates the BP response at
aximal as well as absolute submaximal exercise workloads
nd could prevent an exaggerated BP response in hyperten-
ive patients. We are not aware of any studies assessing the
ffects of antihypertensive therapy on exercise-induced hy-
ertension, or studies comparing the effects of beta-blockers
ith other antihypertensive agents for the prevention of
bnormal exercise-induced hypertension.
The lower BP and HR at absolute submaximal and
aximal workloads suggest improved cardiac performance
nd hemodynamics and a consequent reduction in the work
f the heart. This is further supported by the lower RPP
bserved in those on beta-blocker–based therapy. The
linical significance of these findings extends beyond the
TT. As previously mentioned, the metabolic demand of
ost routine daily and leisure time activities is about 5 to 7
ETs (7). Therefore, it is reasonable to assume that the BP
ecorded at 5 to 7 METs during an exercise stress test
epresents the BP during routine daily activities.
Nevertheless, our findings suggest that beta-blockade, as
onotherapy or in combination with other antihypertensive
edications, may be a prudent approach to control the exag-
erated BP response during exercise observed in some hyper-
ensive patients. This is especially true for hypertensive
atients engaging in vigorous physical activities, such as
CCB Diuretics Untreated p*
223 226 208
117  16† 117  15† 117  17† 0.001
165  25† 166  25† 175  29‡ 0.001
88  14† 90  14† 95  28‡ 0.001
134  16‡ 131  15‡ 132  17‡ 0.001
182  27† 183  27† 183  29† 0.001
88  14 92  14† 92  12† 0.001
149  19‡ 150  16‡ 153  19‡ 0.001
193  30‡ 194  29‡ 204  27‡ 0.001
91  15 94  15† 97  14 0.001
,436  4,454‡ 19,629  4,616‡ 20,647  5,568‡ 0.001
,343  4,869‡ 24,016  5,242‡ 23,919  5,895‡ 0.001
,726  6,257‡ 28,839  5,645‡ 31,220  5,771‡ 0.001
oups. †Bonferroni-corrected probability value 0.05 for the post-hoc comparisons
i-corrected probability value 0.01 for the post-hoc comparisons between other
; other abbreviations as in Tables 1 and 2.19
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Beta-Blockade in Hypertensive Male Patients February 21, 2006:794–8equire repetitive bursts of effort to maximal or near maximal
evels. For these individuals, beta-blockade–based therapy can
rotect against excessive and repetitive elevations in BP that
ay occur during such activities. However, a prospective study
s necessary to confirm our findings and further address the
linical significance of our findings.
Our findings regarding African-American patients are of
articular interest. The risk of having an abnormal BP
esponse during exercise was over 90% higher in African-
merican patients compared with Caucasians. This risk was
ttenuated by 35% with a beta-blocker–based antihyperten-
ive therapy.
Inter-racial comparisons revealed consistently higher BP
nd HR in African-American patients compared with
aucasians at any exercise workload. This was regardless of
he antihypertensive therapy. This suggests that exercise BP
n African-American hypertensive patients is more difficult
o control than in Caucasians regardless of the antihyper-
ensive regimen. Yet, beta-blockers are more effective in
ttenuating the risk of an abnormal exercise BP in African
mericans than other antihypertensive medications. This is
n accord with existing evidence of racial differences in
esponse to different cardiovascular medications and the pro-
ection afforded by these agents (13). However, it is important
o emphasize that we found no statistically significant racial
ifferences on the effects of treatment on BP (no race-by-
reatment interaction). Future prospective studies in sub-
opulations are needed to confirm our findings and help
urther delineate possible antihypertensive agent differences
n the protection against cardiovascular morbid and mortal
vents.
tudy limitations. The present study is cross-sectional and
herefore has limitations. Because of the design we cannot
rovide causal relationships but only state hypotheses to be
valuated in future randomized clinical trials. Smoking
abits have been associated with high BP and low fitness
evels. Although we adjusted for smoking, the use of
elf-reported information may confound our findings. The
nset of hypertension, its severity, and the duration of
ntihypertensive therapy were not evaluated in our study
wing to incomplete records. Finally, our findings are based
n men only and therefore inferences to women are
rohibited.
onclusions. Our findings support that the use of beta-
lockers as monotherapy or in combination with other
ntihypertensive agents mitigates the BP response at max-
mal and absolute submaximal exercise workloads and could
revent an exaggerated BP response in a considerable
roportion of patients. Because the BP response to sub-
aximal exercise workloads of 5 to 7 METs reflects the BP
esponse during routine daily activities, beta-blockade–xcessive rise in BP during routine daily activities in
ypertensive patients who exhibit an excessive BP response
uring exercise testing. Moreover, for patients engaging in
igorous activities such as snow-shoveling, basketball, ten-
is, racquetball, and so on, beta-blockade–based therapy
an protect against excessive and repetitive elevations in BP
hich may occur during such activities. The need for a
rospective study to further address the clinical significance
f the current findings is necessary.
eprint requests and correspondence: Dr. Peter Kokkinos, Cardi-
logy Division, Veterans Affairs Medical Center, 50 Irving Street,
W, Washington, DC 20422. E-mail: peter.kokkinos@med.va.gov.
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